The effect of cilostazol on the angiographic outcome of drug-eluting coronary stents angiographic analysis of the CILON-T (Influence of cilostazol-based triple antiplatelet therapy on ischemi complication after drug-eluting stent implantation) trial

Jung Won Suh, Seung Pyo Lee, Kyungwoo Park, Hyun Jae Kang, Bon Kwon Koo, Young Seok Cho, Tae Jin Youn, In Ho Chae, Dong Ju Choi, Seung-Woon Rha, Jang Ho Bae, Taek Geun Kwon, Jang Whan Bae, Myeong Chan Cho, Hyo Soo Kim

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

It is not clear if anti-restonotic effect of cilostazol is consistent for different types of drug-eluting stents (DES). The purpose of this study was to compare the anti-proliferative effect of cilostazol between DAT and TAT with consideration of confounding influences of DES type. Nine hundred and fifteen patients were randomized to either dual antiplatelet therapy (DAT; aspirin and clopidogrel) or triple antiplatelet therapy (TAT; aspirin, clopidogrel, and cilostazol) in the previous CILON-T trial. After excluding 70 patients who received both or neither stents, we analyzed 845 patients who received exclusively PES or ZES, and compared in-stent late loss at 6 months between both antiplatelet regimens (DAT versus TAT). Baseline angiographic and clinical characteristics were similar between the DAT (656 lesions in 425 patients) and the TAT group (600 lesions in 420 patients). The 6-month follow-up angiography was completed in 745 patients (88.2%). Quantitative coronary angiography showed that TAT significantly reduced in-stent late loss (DAT 0.62 ± 0.62 mm versus TAT 0.54 ± 0.49 mm, P = 0.015). Stent type, diabetes or lesion length did not interact with difference of late loss. However, reduction of late loss by cilostazol did not lead to a significant reduction in the rate of target lesion revascularization (TLR) (DAT 7.8% versus TAT 6.9%, P = 0.69) due to a nonlinear relationship found between late loss and TLR. The TAT group showed less in-stent late loss as compared to the DAT group. This was consistently observed regardless of DES type, lesion length, or diabetic status. However, reduction of late loss by cilostazol did not lead to a significant reduction in TLR.

Original languageEnglish
Pages (from-to)853-860
Number of pages8
JournalInternational Heart Journal
Volume58
Issue number6
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Drug-Eluting Stents
clopidogrel
Stents
Aspirin
Therapeutics
Coronary Angiography
cilostazol
Angiography

Keywords

  • Cilostazol
  • Paclitaxel-eluting stent
  • Restenosis
  • Zotarolimus-eluting stent

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

The effect of cilostazol on the angiographic outcome of drug-eluting coronary stents angiographic analysis of the CILON-T (Influence of cilostazol-based triple antiplatelet therapy on ischemi complication after drug-eluting stent implantation) trial. / Suh, Jung Won; Lee, Seung Pyo; Park, Kyungwoo; Kang, Hyun Jae; Koo, Bon Kwon; Cho, Young Seok; Youn, Tae Jin; Chae, In Ho; Choi, Dong Ju; Rha, Seung-Woon; Bae, Jang Ho; Kwon, Taek Geun; Bae, Jang Whan; Cho, Myeong Chan; Kim, Hyo Soo.

In: International Heart Journal, Vol. 58, No. 6, 01.01.2017, p. 853-860.

Research output: Contribution to journalArticle

Suh, Jung Won ; Lee, Seung Pyo ; Park, Kyungwoo ; Kang, Hyun Jae ; Koo, Bon Kwon ; Cho, Young Seok ; Youn, Tae Jin ; Chae, In Ho ; Choi, Dong Ju ; Rha, Seung-Woon ; Bae, Jang Ho ; Kwon, Taek Geun ; Bae, Jang Whan ; Cho, Myeong Chan ; Kim, Hyo Soo. / The effect of cilostazol on the angiographic outcome of drug-eluting coronary stents angiographic analysis of the CILON-T (Influence of cilostazol-based triple antiplatelet therapy on ischemi complication after drug-eluting stent implantation) trial. In: International Heart Journal. 2017 ; Vol. 58, No. 6. pp. 853-860.
@article{48781287746545088012561a168ad738,
title = "The effect of cilostazol on the angiographic outcome of drug-eluting coronary stents angiographic analysis of the CILON-T (Influence of cilostazol-based triple antiplatelet therapy on ischemi complication after drug-eluting stent implantation) trial",
abstract = "It is not clear if anti-restonotic effect of cilostazol is consistent for different types of drug-eluting stents (DES). The purpose of this study was to compare the anti-proliferative effect of cilostazol between DAT and TAT with consideration of confounding influences of DES type. Nine hundred and fifteen patients were randomized to either dual antiplatelet therapy (DAT; aspirin and clopidogrel) or triple antiplatelet therapy (TAT; aspirin, clopidogrel, and cilostazol) in the previous CILON-T trial. After excluding 70 patients who received both or neither stents, we analyzed 845 patients who received exclusively PES or ZES, and compared in-stent late loss at 6 months between both antiplatelet regimens (DAT versus TAT). Baseline angiographic and clinical characteristics were similar between the DAT (656 lesions in 425 patients) and the TAT group (600 lesions in 420 patients). The 6-month follow-up angiography was completed in 745 patients (88.2{\%}). Quantitative coronary angiography showed that TAT significantly reduced in-stent late loss (DAT 0.62 ± 0.62 mm versus TAT 0.54 ± 0.49 mm, P = 0.015). Stent type, diabetes or lesion length did not interact with difference of late loss. However, reduction of late loss by cilostazol did not lead to a significant reduction in the rate of target lesion revascularization (TLR) (DAT 7.8{\%} versus TAT 6.9{\%}, P = 0.69) due to a nonlinear relationship found between late loss and TLR. The TAT group showed less in-stent late loss as compared to the DAT group. This was consistently observed regardless of DES type, lesion length, or diabetic status. However, reduction of late loss by cilostazol did not lead to a significant reduction in TLR.",
keywords = "Cilostazol, Paclitaxel-eluting stent, Restenosis, Zotarolimus-eluting stent",
author = "Suh, {Jung Won} and Lee, {Seung Pyo} and Kyungwoo Park and Kang, {Hyun Jae} and Koo, {Bon Kwon} and Cho, {Young Seok} and Youn, {Tae Jin} and Chae, {In Ho} and Choi, {Dong Ju} and Seung-Woon Rha and Bae, {Jang Ho} and Kwon, {Taek Geun} and Bae, {Jang Whan} and Cho, {Myeong Chan} and Kim, {Hyo Soo}",
year = "2017",
month = "1",
day = "1",
doi = "10.1536/ihj.16-332",
language = "English",
volume = "58",
pages = "853--860",
journal = "International Heart Journal",
issn = "1349-2365",
publisher = "International Heart Journal Association",
number = "6",

}

TY - JOUR

T1 - The effect of cilostazol on the angiographic outcome of drug-eluting coronary stents angiographic analysis of the CILON-T (Influence of cilostazol-based triple antiplatelet therapy on ischemi complication after drug-eluting stent implantation) trial

AU - Suh, Jung Won

AU - Lee, Seung Pyo

AU - Park, Kyungwoo

AU - Kang, Hyun Jae

AU - Koo, Bon Kwon

AU - Cho, Young Seok

AU - Youn, Tae Jin

AU - Chae, In Ho

AU - Choi, Dong Ju

AU - Rha, Seung-Woon

AU - Bae, Jang Ho

AU - Kwon, Taek Geun

AU - Bae, Jang Whan

AU - Cho, Myeong Chan

AU - Kim, Hyo Soo

PY - 2017/1/1

Y1 - 2017/1/1

N2 - It is not clear if anti-restonotic effect of cilostazol is consistent for different types of drug-eluting stents (DES). The purpose of this study was to compare the anti-proliferative effect of cilostazol between DAT and TAT with consideration of confounding influences of DES type. Nine hundred and fifteen patients were randomized to either dual antiplatelet therapy (DAT; aspirin and clopidogrel) or triple antiplatelet therapy (TAT; aspirin, clopidogrel, and cilostazol) in the previous CILON-T trial. After excluding 70 patients who received both or neither stents, we analyzed 845 patients who received exclusively PES or ZES, and compared in-stent late loss at 6 months between both antiplatelet regimens (DAT versus TAT). Baseline angiographic and clinical characteristics were similar between the DAT (656 lesions in 425 patients) and the TAT group (600 lesions in 420 patients). The 6-month follow-up angiography was completed in 745 patients (88.2%). Quantitative coronary angiography showed that TAT significantly reduced in-stent late loss (DAT 0.62 ± 0.62 mm versus TAT 0.54 ± 0.49 mm, P = 0.015). Stent type, diabetes or lesion length did not interact with difference of late loss. However, reduction of late loss by cilostazol did not lead to a significant reduction in the rate of target lesion revascularization (TLR) (DAT 7.8% versus TAT 6.9%, P = 0.69) due to a nonlinear relationship found between late loss and TLR. The TAT group showed less in-stent late loss as compared to the DAT group. This was consistently observed regardless of DES type, lesion length, or diabetic status. However, reduction of late loss by cilostazol did not lead to a significant reduction in TLR.

AB - It is not clear if anti-restonotic effect of cilostazol is consistent for different types of drug-eluting stents (DES). The purpose of this study was to compare the anti-proliferative effect of cilostazol between DAT and TAT with consideration of confounding influences of DES type. Nine hundred and fifteen patients were randomized to either dual antiplatelet therapy (DAT; aspirin and clopidogrel) or triple antiplatelet therapy (TAT; aspirin, clopidogrel, and cilostazol) in the previous CILON-T trial. After excluding 70 patients who received both or neither stents, we analyzed 845 patients who received exclusively PES or ZES, and compared in-stent late loss at 6 months between both antiplatelet regimens (DAT versus TAT). Baseline angiographic and clinical characteristics were similar between the DAT (656 lesions in 425 patients) and the TAT group (600 lesions in 420 patients). The 6-month follow-up angiography was completed in 745 patients (88.2%). Quantitative coronary angiography showed that TAT significantly reduced in-stent late loss (DAT 0.62 ± 0.62 mm versus TAT 0.54 ± 0.49 mm, P = 0.015). Stent type, diabetes or lesion length did not interact with difference of late loss. However, reduction of late loss by cilostazol did not lead to a significant reduction in the rate of target lesion revascularization (TLR) (DAT 7.8% versus TAT 6.9%, P = 0.69) due to a nonlinear relationship found between late loss and TLR. The TAT group showed less in-stent late loss as compared to the DAT group. This was consistently observed regardless of DES type, lesion length, or diabetic status. However, reduction of late loss by cilostazol did not lead to a significant reduction in TLR.

KW - Cilostazol

KW - Paclitaxel-eluting stent

KW - Restenosis

KW - Zotarolimus-eluting stent

UR - http://www.scopus.com/inward/record.url?scp=85038383895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038383895&partnerID=8YFLogxK

U2 - 10.1536/ihj.16-332

DO - 10.1536/ihj.16-332

M3 - Article

C2 - 29118299

AN - SCOPUS:85038383895

VL - 58

SP - 853

EP - 860

JO - International Heart Journal

JF - International Heart Journal

SN - 1349-2365

IS - 6

ER -